Efficacy and safety of lenvatinib in hepatocellular carcinoma patients with liver transplantation: A case-control study

Yen Yang Chen, Chao Long Chen, Chih Che Lin, Chih Chi Wang, Yueh Wei Liu, Wei Feng Li, Yen Hao Chen*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

12 Scopus citations

Abstract

Tumor recurrence is the most common cause of death in hepatocellular carcinoma (HCC) patients who received liver transplantation (LT). Recently, lenvatinib was approved for the systemic treatment of unresectable HCC patients; however, the role of lenvatinib in HCC patients after LT remains unclear. There were 56 patients with recurrent HCC after LT from 2008 to 2018 in our in-stitute, and 10 patients who received lenvatinib were identified. Additionally, to understand the difference in the clinical impact of lenvatinib in the LT and non-LT settings, 25 HCC patients without LT who underwent lenvatinib treatment were identified from our HCC database and regarded as the control group. In the LT group, partial response was 20% and stable disease was 50%, resulting in a disease control rate of 70%; the median progression-free survival (PFS), time to treatment failure (TTF) and overall survival (OS) were 3.7, 3.6 and 16.4 months, respectively. Adverse events (AEs) were predominantly grade 1–2 in severity, and the majority of patients tolerated the side ef-fects. There was no significant difference in PFS/OS, and we observed a similar pattern of AEs between these two groups. Our study confirms the comparable efficacy and safety of lenvatinib in HCC patients with LT and non-LT in clinical practice.

Original languageEnglish
Article number4584
JournalCancers
Volume13
Issue number18
DOIs
StatePublished - 09 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

  • Hepatocellular carcinoma
  • Lenvatinib
  • Liver transplantation
  • Safety
  • Survival

Fingerprint

Dive into the research topics of 'Efficacy and safety of lenvatinib in hepatocellular carcinoma patients with liver transplantation: A case-control study'. Together they form a unique fingerprint.

Cite this